All In Biotech

Drug Trial Radar · NCT00001030

The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients

A Prospective, Randomized, Comparative Study of the Safety and Efficacy of Clarithromycin Versus Rifabutin Versus the Combination of Clarithromycin Plus Rifabutin for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia or Disseminated MAC Disease in HIV-Infected Patients With CD4 Lymphocyte Counts <= 100 Cells/mm3

Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,100

Actual

Start

Not stated

Primary completion

Not stated

Study completion Jun 1996

Sponsor

Sponsor type
NIH
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy and safety of clarithromycin alone versus rifabutin alone versus the two drugs in combination for the prevention or delay of Mycobacterium avium Complex (MAC) bacteremia or disseminated MAC disease. To compare other parameters such as survival, toxicity, and quality of life among the three treatment arms. To obtain information on the incidence and clinical grade of targeted gynecologic conditions. Persons with advanced stages of HIV are considered to be at particular risk for developing disseminated MAC disease. The development of an effective regimen for the prevention of disseminated MAC disease may be of substantial benefit in altering the morbidity and possibly the mortality associated with this disease and its treatment.

Conditions

  • Mycobacterium Avium-intracellulare Infection
  • HIV Infections

Interventions

  • ClarithromycinDrug

  • RifabutinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

42 sites in 2 countries. Site status is shown where the registry gives one.

  • Alabama Therapeutics CRS

    Birmingham, Alabama

  • UCLA CARE Center CRS

    Los Angeles, California

  • Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab.

    Oakland, California

  • Ucsf Aids Crs

    San Francisco, California

  • Howard University Hosp., Div. of Infectious Diseases, ACTU

    Washington D.C., District of Columbia

  • Univ. of Miami AIDS CRS

    Miami, Florida

  • Univ. of Hawaii at Manoa, Leahi Hosp.

    Honolulu, Hawaii

  • Chicago Children's CRS

    Chicago, Illinois

  • Northwestern University CRS

    Chicago, Illinois

  • Cook County Hosp. CORE Ctr.

    Chicago, Illinois

  • Rush Univ. Med. Ctr. ACTG CRS

    Chicago, Illinois

  • Indiana Univ. School of Medicine, Infectious Disease Research Clinic

    Indianapolis, Indiana

  • Methodist Hosp. of Indiana

    Indianapolis, Indiana

  • Univ. of Iowa Healthcare, Div. of Infectious Diseases

    Iowa City, Iowa

  • Johns Hopkins Adult AIDS CRS

    Baltimore, Maryland

  • Massachusetts General Hospital ACTG CRS

    Boston, Massachusetts

  • Bmc Actg Crs

    Boston, Massachusetts

  • Beth Israel Deaconess - East Campus A0102 CRS

    Boston, Massachusetts

  • Beth Israel Deaconess Med. Ctr., ACTG CRS

    Boston, Massachusetts

  • Hennepin County Med. Ctr., Div. of Infectious Diseases

    Minneapolis, Minnesota

  • University of Minnesota, ACTU

    Minneapolis, Minnesota

  • St. Louis ConnectCare, Infectious Diseases Clinic

    St Louis, Missouri

  • Washington U CRS

    St Louis, Missouri

  • Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr.

    Omaha, Nebraska

  • SUNY - Buffalo, Erie County Medical Ctr.

    Buffalo, New York

  • NY Univ. HIV/AIDS CRS

    New York, New York

  • Memorial Sloan-Kettering Cancer Ctr.

    New York, New York

  • Beth Israel Med. Ctr. (Mt. Sinai)

    New York, New York

  • Cornell University A2201

    New York, New York

  • Univ. of Rochester ACTG CRS

    Rochester, New York

  • Bronx-Lebanon Hosp. IMPAACT CRS

    The Bronx, New York

  • Unc Aids Crs

    Chapel Hill, North Carolina

  • Carolinas HealthCare System, Carolinas Med. Ctr.

    Charlotte, North Carolina

  • Regional Center for Infectious Disease, Wendover Medical Center CRS

    Greensboro, North Carolina

  • Univ. of Cincinnati CRS

    Cincinnati, Ohio

  • Case CRS

    Cleveland, Ohio

  • MetroHealth CRS

    Cleveland, Ohio

  • The Ohio State Univ. AIDS CRS

    Columbus, Ohio

  • Hosp. of the Univ. of Pennsylvania CRS

    Philadelphia, Pennsylvania

  • The Children's Hosp. of Philadelphia IMPAACT CRS

    Philadelphia, Pennsylvania

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.